Navigation Links
Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis

with substantial manufacturing costs and inconvenience for patients.

CYT007-TNFQb is a therapeutic vaccine in development for the treatment of psoriasis and other inflammatory conditions. It is designed to instruct the patient’s immune system to produce an anti- TNF-? antibody response. The induced antibodies aim to bind TNF-? in order to inhibit its inflammatory activity. That way, the subsequent inflammatory process should be slowed down and the deterioration of skin or other tissues reduced.

For further information please contact:
Cytos Biotechnology AG, Wagistrasse 25, CH-8952 Schlieren
Claudine Blaser, PhD
Director Corporate Communications
Tel.: +41 44 733 47 20
e-Mail: claudine.blaser@cytos.com
Webseite: www.cytos.com


About Cytos Biotechnology AG
Cytos Biotechnology AG is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the ImmunodrugsTM. ImmunodrugsTM are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. ImmunodrugsTM are designed to instruct the patient’s immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its
ImmunodrugTM platform, Cytos Biotechnology has built a pipeline of different ImmunodrugTM candidates in various disease areas, of which 6 are currently in clinical development. The ImmunodrugTM candidates are developed both in-house and together with Novartis and Pfizer Animal Health. Founded in 1995 as a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich, the company is located in Schlieren (Zurich). Currently, the company has
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia

Post Your Comments:
(Date:11/20/2009)...nn., Nov. 20 Smith &am... pleased to announce the signing of a technology d...ent of Defense that may lead to the creation of a ... the treatment of the limbs of soldiers who sustai...se Advanced Research Projects Agency (DARPA), the ...
(Date:11/19/2009)..., Colo., Nov. 19 In a se...experience, Heska Corporation (Nasdaq: HSKA ) ("H... of its new and improved website. The upgraded si...sign and programming to align the site with the co... ,, (Logo: http://www.newscom.com/cgi-bin/prn...
(Date:11/19/2009)...E, Mass., Nov. 19 Ligon Discovery,...array technology to find drugs against high-value ... seed financing led by incTANK Ventures. The compa...scovery campaign that will screen over 100 high-va... incTANK Ventures General Partner Christian Bailey...
Breaking Medicine Technology:Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3Analysis of the Proposed Health Care Legislation Finds Financial Aspects May be Difficult to Forecast 54474 1Analysis of the Proposed Health Care Legislation Finds Financial Aspects May be Difficult to Forecast 54474 2Verizon Introduces New IT Security Capabilities for Health Care Industry 54471 1Verizon Introduces New IT Security Capabilities for Health Care Industry 54471 2Verizon Introduces New IT Security Capabilities for Health Care Industry 54471 3Verizon Introduces New IT Security Capabilities for Health Care Industry 54471 4China Kangtai Cactus Biotech Q2 Revenue Up 30 25 to Record 246 5M 3B Net Income Up 37 25 to 241 4M EPS 240 07 54468 1China Kangtai Cactus Biotech Q2 Revenue Up 30 25 to Record 246 5M 3B Net Income Up 37 25 to 241 4M EPS 240 07 54468 2China Kangtai Cactus Biotech Q2 Revenue Up 30 25 to Record 246 5M 3B Net Income Up 37 25 to 241 4M EPS 240 07 54468 3China Kangtai Cactus Biotech Q2 Revenue Up 30 25 to Record 246 5M 3B Net Income Up 37 25 to 241 4M EPS 240 07 54468 4
...icromet, Inc.,(Nasdaq: MITI ), a biopharmaceutic...s for the treatment of cancer, inflammation and au...s anticipated for the year 2009. , Micromet in...elopment,programs at the following events: , -...cal BiTE antibodies at,the American Association fo...
...3 Warner Chilcott Limited (Nasdaq: WCRX ) annou...Pharma International Pty. Ltd. ("Mayne"), a subsid... each of Mutual Pharmaceutical Company, Inc. ("Mut...pax Laboratories, Inc. ("Impax") in the District ...ent of Mayne,s U.S. Patent No. 6,958,161 (the ",16...
Other Medicine Technology:Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3
(Date:11/20/2009)...WASHINGTON, Nov. 20 The...d the Senate to make essential changes its health ...on abortion funding and conscience protection on a...nts and include strong provisions for adequate aff...alth care bill an "enormous disappointment" that c...
(Date:11/20/2009).... LOUIS, Nov. 20 Cente... it will present at the Bank of America Merrill Ly...3, 2009, at the Crowne Plaza Hotel Times Square in...ay, December 2nd at 8:30 a.m. Eastern Time. Invest..., audio webcast of Centene,s presentation at: htt...
(Date:11/20/2009)...ublished online November 20 in the Journal of the...ted fears and hopes that often appear in news cove...idance for both the media and journals to help all...S., and Steven Woloshin, M.D., M.S., of Center for... for Health Policy and Clinical Practice in New Ha...
(Date:11/20/2009)...,s as short as 34 weeks, potentially adding to pre...AY, Nov. 20 (HealthDay News) -- Recent reports sho... climb in the United States. Now, a new study sug...t what constitutes a full-term birth in the first ...yed in the study considered a baby born at 34 to 3...
(Date:11/20/2009)...roject Bread addresses increased food insecurity a...20 Project Bread, the s...numbers from its upcoming annual status report on ... described in this report, caused by high unemploy...struggling with hunger. Food insecurity has found ...
Breaking Medicine News(10 mins):Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4Health News:554,000 in Massachusetts Struggle to Put Food on the Table 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 3Health News:554,000 in Massachusetts Struggle to Put Food on the Table 4
...ercentenarian Research Foundation has been set up ... people aged more than 110 years. //The aim is to ...lop tactics to conquer the aging effects and have ...hen Coles, the foundation's treasurer and a resear...
...survivors now have an explanation for their mental...t away as a figment of their imagination//. ...anges to the brain's metabolism and blood flow tha...s may help to explain the disrupted thought proces...
...rent association linking genes, diet and heart dis... Jean Mayer// USDA Human Nutrition Research Center...y involved examination of apolipoprotein A5 (APOA5... heart disease, which can be altered by consumptio...
...opkins researchers have teased out the function of... a rare cognitive disorder associated with overly ...alled TFII-I, or TF “two eye,” the protein long kn...he study will be published this week in Science. ...
...-rays were discovered more than a century ago, tri...s have sought more powerful ways to "see" into the...t from the John R. Oishei Foundation, researchers ... nanoparticle-based multi-probe systems, launching...
...pes of anxiety disorders and phobias are more comm...and Phobias, a new report from Harvard Medical Sch...gical factors, as well as differences in experienc... are three times as likely to have agoraphobia (fe...
Other Medicine News:Health News:Supercentenarian Center to study longevity 2Health News:Chemotherapy's Effects on the Brain 2Health News:Chemotherapy's Effects on the Brain 3Health News:The interplay of genes, diet and heart disease 2Health News:The interplay of genes, diet and heart disease 3Health News:The interplay of genes, diet and heart disease 4Health News:Researchers Uncover Critical Player in Cell Communication 2Health News:Hybrid Nanoparticles for Multimodal Medical Imaging 2Health News:Hybrid Nanoparticles for Multimodal Medical Imaging 3
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products: